Initial Antibiotic Therapy for Gram-Positive Cocci Infections
For GPC infections with possible MRSA involvement, your initial antibiotic choice depends critically on infection severity and location: use oral clindamycin (300-450 mg TID), TMP-SMX (1-2 DS tabs BID), or doxycycline (100 mg BID) for outpatient purulent skin infections; use IV vancomycin (15-20 mg/kg every 8-12h) for hospitalized patients with complicated infections or bacteremia 1.
Outpatient Management
Purulent Skin and Soft Tissue Infections
For outpatients with purulent cellulitis or abscesses requiring antibiotics (after incision and drainage when applicable):
First-line oral options for MRSA coverage 1:
- Clindamycin 300-450 mg PO TID (covers both MRSA and streptococci)
- TMP-SMX 1-2 double-strength tablets BID (MRSA only—add amoxicillin 500 mg TID if streptococcal coverage needed)
- Doxycycline 100 mg PO BID (MRSA only—add beta-lactam for streptococci)
- Linezolid 600 mg PO BID (covers both, but more expensive)
Duration: 5-10 days based on clinical response 1.
Nonpurulent Cellulitis
For cellulitis without purulent drainage or abscess, start with a beta-lactam (cephalexin 500 mg QID or dicloxacillin) targeting streptococci 1. Only add MRSA coverage if the patient fails to respond or has systemic toxicity.
Inpatient Management
Complicated Skin and Soft Tissue Infections
For hospitalized patients with deeper infections, surgical wounds, major abscesses, or systemic toxicity, empirical IV MRSA coverage is essential 1:
First-line IV options:
- Vancomycin 15-20 mg/kg IV every 8-12h (target trough 15-20 mg/L for serious infections)
- Linezolid 600 mg IV/PO BID
- Daptomycin 4 mg/kg IV daily (for skin infections; use 6 mg/kg for bacteremia)
- Clindamycin 600 mg IV TID (if local resistance <10%)
Duration: 7-14 days based on clinical response 1.
Bacteremia and Endocarditis
For MRSA bacteremia, vancomycin or daptomycin are the definitive choices 1:
- Vancomycin 15-20 mg/kg IV every 8-12h
- Daptomycin 6 mg/kg IV daily (higher dose than for skin infections; proven effective for bacteremia and right-sided endocarditis) 2
Pneumonia
Never use daptomycin for pneumonia—it is inactivated by pulmonary surfactant 3. Use:
- Vancomycin 15-20 mg/kg IV every 8-12h
- Linezolid 600 mg IV/PO BID
Pediatric Considerations
Dosing adjustments 1:
- Vancomycin: 15 mg/kg IV every 6h
- Clindamycin: 10-13 mg/kg every 6-8h (max 40 mg/kg/day)
- Linezolid: 10 mg/kg every 8h (<12 years); 600 mg BID (≥12 years)
- Avoid tetracyclines in children <8 years
- Avoid TMP-SMX in children <2 months and third-trimester pregnancy
Critical Decision Points
When to suspect MRSA empirically:
- Purulent drainage or exudate present
- Failed beta-lactam therapy
- Systemic toxicity
- Known high local MRSA prevalence
- Healthcare-associated infection
Common pitfalls:
- Vancomycin underdosing: Target troughs of 15-20 mg/L for serious infections, not the outdated 5-10 mg/L range 2
- Using daptomycin for pneumonia (contraindicated due to surfactant inactivation) 3
- Clindamycin monotherapy where resistance exceeds 10% locally 1
- Rifampin monotherapy (never use alone) 1
Culture guidance: Always obtain cultures from purulent infections before starting antibiotics in patients requiring antimicrobial therapy, those with severe infection, or those failing initial treatment 1. This allows de-escalation and resistance monitoring.
The IDSA guidelines emphasize that inadequate initial antibiotic therapy for resistant gram-positive infections is associated with higher mortality 3, making appropriate empirical coverage essential while awaiting culture results.